Cart
sales@molnova.com
Tibolone
CAS No. 5630-53-5
Tibolone ( Tibolone ; Xyvion; Tibolonum )
Catalog No. M18813 CAS No. 5630-53-5
Tibolone is an estrogen-like compound used for the treatment of the symptoms associated with menopausal transition (i.e., climacteric symptoms) and also for the treatment of osteoporosis.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTibolone
-
NoteResearch use only, not for human use.
-
Brief DescriptionTibolone is an estrogen-like compound used for the treatment of the symptoms associated with menopausal transition (i.e., climacteric symptoms) and also for the treatment of osteoporosis.
-
DescriptionTibolone is an estrogen-like compound used for the treatment of the symptoms associated with menopausal transition (i.e., climacteric symptoms) and also for the treatment of osteoporosis.
-
SynonymsTibolone ; Xyvion; Tibolonum
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorER
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number5630-53-5
-
Formula Weight312.45
-
Molecular FormulaC21H28O2
-
Purity98%
-
Solubility——
-
SMILESC[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)C#C)[C@H]12
-
Chemical Name19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7alpha,17alpha)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kloosterboer HJ.etal.Tissue-selectivity: the mechanism of action of tibolone.Maturitas. 2004 Aug 30;48 Suppl 1:S30-40.
molnova catalog
related products
-
NVP-BKM120
NVP-BKM120 (BKM-120, Buparlisib)is a potent, selective, orally bioavailable inhibitor of class I PI3K isoforms.
-
PQR309
PQR309 (Bimiralisib) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50 of 33, 451, 661, 708 and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively.
-
Loureirin A
Loureirin A has an inhibitory effect on platelet activation perhaps through an impairment of PI3K/Akt signaling.Loureirin A negatively affects agonist-induced platelet aggregation such as collagen collagen-related peptide (CRP) ADP and thrombin.
